Literature DB >> 3128395

Thrombolytic therapy for myocardial infarction: the problem, the promise and the price.

D D Waters1, A Wiseman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3128395      PMCID： PMC1267737     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

Review 1.  Pharmacology of thrombolytic drugs.

Authors:  M Verstraete; D Collen
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094

2.  A cost-effectiveness model for coronary thrombolysis/reperfusion therapy.

Authors:  G L Laffel; H V Fineberg; E Braunwald
Journal:  J Am Coll Cardiol       Date:  1987-11       Impact factor: 24.094

3.  The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report.

Authors:  J W Kennedy; J L Ritchie; K B Davis; M L Stadius; C Maynard; J K Fritz
Journal:  N Engl J Med       Date:  1985-04-25       Impact factor: 91.245

4.  The prehospital course of patients with chest pain. Analysis of the prodromal, symptomatic, decision-making, transportation and emergency room periods.

Authors:  J S Schroeder; I H Lamb; M Hu
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

5.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

6.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; M Takayama; A Maslowski; N M Bass; J A Ormiston; T Whitlock
Journal:  N Engl J Med       Date:  1987-10-01       Impact factor: 91.245

7.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

Authors:  E J Topol; R M Califf; B S George; D J Kereiakes; C W Abbottsmith; R J Candela; K L Lee; B Pitt; R S Stack; W W O'Neill
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

8.  Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.

Authors:  M Verstraete; R Bernard; M Bory; R W Brower; D Collen; D P de Bono; R Erbel; W Huhmann; R J Lennane; J Lubsen
Journal:  Lancet       Date:  1985-04-13       Impact factor: 79.321

9.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.

Authors:  M A DeWood; J Spores; R Notske; L T Mouser; R Burroughs; M S Golden; H T Lang
Journal:  N Engl J Med       Date:  1980-10-16       Impact factor: 91.245
  9 in total
  2 in total

1.  Medical devices labelled for single use: the reuse of permanent cardiac pacemakers.

Authors:  M Rosengarten
Journal:  CMAJ       Date:  1989-06-01       Impact factor: 8.262

Review 2.  Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

Authors:  L B Barradell; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.